Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Other Non-Current Assets (2021 - 2025)

Indivior Pharmaceuticals has reported Other Non-Current Assets over the past 5 years, most recently at $27.0 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $27.0 million for Q4 2025, down 30.77% from a year ago — trailing twelve months through Dec 2025 was $27.0 million (down 30.77% YoY), and the annual figure for FY2025 was $27.0 million, down 30.77%.
  • Other Non-Current Assets for Q4 2025 was $27.0 million at Indivior Pharmaceuticals, roughly flat from $27.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for INDV hit a ceiling of $106.0 million in Q4 2021 and a floor of $27.0 million in Q3 2025.
  • Median Other Non-Current Assets over the past 5 years was $38.5 million (2022), compared with a mean of $44.5 million.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 64.15% in 2022 and later rose 8.33% in 2024.
  • Indivior Pharmaceuticals' Other Non-Current Assets stood at $106.0 million in 2021, then tumbled by 64.15% to $38.0 million in 2022, then dropped by 5.26% to $36.0 million in 2023, then increased by 8.33% to $39.0 million in 2024, then crashed by 30.77% to $27.0 million in 2025.
  • The last three reported values for Other Non-Current Assets were $27.0 million (Q4 2025), $27.0 million (Q3 2025), and $44.0 million (Q2 2025) per Business Quant data.